IOL Chemicals & Pharmaceuticals' Q3 FY 2025-26 Quarterly Results
- 12 Feb 2026
Result Summary
- IOL Chemicals & Pharmaceuticals Ltd reported a 2.0% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 11.1%.
- Its expenses for the quarter were up by 2.4% QoQ and 9.5% YoY.
- The net profit decreased 31.3% QoQ and increased 0.2% YoY.
- The earnings per share (EPS) of IOL Chemicals & Pharmaceuticals Ltd stood at 0.7 during Q3 FY 2025-26.
Financial Statments for Q3 FY 2025-26
Total Income | 585.68 | 574.41 | 527.37 | 2.0% | 11.1% |
Total Expenses | 546.92 | 533.92 | 499.57 | 2.4% | 9.5% |
Profit Before Tax | 27.55 | 40.49 | 27.80 | -32.0% | -0.9% |
Tax | 6.97 | 10.52 | 7.27 | -33.7% | -4.1% |
Profit After Tax | 20.58 | 29.97 | 20.53 | -31.3% | 0.2% |
Earnings Per Share | 0.70 | 1.02 | 3.50 | -31.4% | -80.0% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
IOL Chemicals & Pharmaceuticals Ltd is a prominent player in the chemicals and pharmaceuticals industry, primarily engaged in the manufacturing and sale of active pharmaceutical ingredients (APIs) and specialty chemicals. The company is known for its expertise in producing bulk drugs and specialty chemicals, catering to a broad spectrum of industries including pharmaceuticals, agriculture, and more. While specific recent developments are not detailed in the provided data, the company is likely involved in ongoing product innovation and expansion efforts typical of industry leaders. As of now, further specifics regarding recent major developments or strategic initiatives are not available in the provided data.
Revenue
In the third quarter of fiscal year 2026, IOL Chemicals & Pharmaceuticals Ltd reported a total income of ₹585.68 crores. This reflects a 2.0% increase compared to the previous quarter's income of ₹574.41 crores. On a year-over-year basis, the total income increased by 11.1% from ₹527.37 crores in the third quarter of fiscal year 2025. This growth in revenue indicates a positive trajectory in the company's financial performance over both the quarterly and annual periods under review. The revenue growth is a key indicator of the company's ability to enhance its market position and capitalize on its product offerings.
Profitability
The company's profitability metrics for the third quarter of fiscal year 2026 show a profit before tax of ₹27.55 crores, which is a decrease of 32.0% from the previous quarter's profit before tax of ₹40.49 crores. Compared to the same quarter last year, there is a slight decrease of 0.9% from ₹27.80 crores. The profit after tax for Q3FY26 stands at ₹20.58 crores, marking a 31.3% decline from the preceding quarter's ₹29.97 crores, but a marginal increase of 0.2% from ₹20.53 crores in Q3FY25. The earnings per share for Q3FY26 is ₹0.70, which is significantly lower than the ₹1.02 reported in Q2FY26 and the ₹3.50 reported in Q3FY25, representing a decrease of 31.4% and 80.0% respectively.
Operating Metrics
The total expenses for IOL Chemicals & Pharmaceuticals Ltd in the third quarter of fiscal year 2026 amounted to ₹546.92 crores, showing an increase of 2.4% from ₹533.92 crores in the previous quarter. Year-over-year, there is a 9.5% increase from the ₹499.57 crores recorded in the third quarter of fiscal year 2025. The tax expense for Q3FY26 is ₹6.97 crores, which reflects a decrease of 33.7% from the previous quarter's tax expense of ₹10.52 crores and a 4.1% decrease from ₹7.27 crores in Q3FY25. These operating metrics highlight the financial dynamics of the company in terms of cost management and fiscal obligations over the reviewed periods.